Elequin Capital’s NeoGenomics NEO Stock Holding History

Elequin Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6	Closed	-$71	–	702
2025 Q4	$71	Buy	+6	New	+$65	﹤0.01%	405
2025 Q3	–	Sell	-2	Closed	-$15	–	299
2025 Q2	$15	Buy	+2	New	+$16	﹤0.01%	367
2024 Q4	–	Sell	-18	Closed	-$266	–	592
2024 Q3	$266	Buy	+18	New	+$282	﹤0.01%	353
2024 Q2	–	Sell	-81	Closed	-$1.27K	–	292
2024 Q1	$1.27K	Buy	81 +76	+1,520%	+$1.17K	﹤0.01%	193
2023 Q4	$81	Sell	5 -1	-17%	-$16	﹤0.01%	344
2023 Q3	$74	Sell	6 -150	-96%	-$2.23K	﹤0.01%	377
2023 Q2	$2.51K	Buy	+156	New	+$2.57K	﹤0.01%	429
2022 Q3	–	Sell	-22	Closed	–	–	633
2022 Q2	$0	Sell	22 -1	-4%	-$10	﹤0.01%	423
2022 Q1	$0	Buy	+23	New	+$484	﹤0.01%	331

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Elequin Capital's NEO Position: Q1 2026 in Review

Elequin Capital sold out of NeoGenomics (NEO) in Q1 2026, closing a stake of 6 shares — an estimated $71 sold.

Elequin Capital first reported a position in NEO in Q1 2022 and held it in 9 quarters. The position peaked at $2.51K in Q2 2023. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

Elequin Capital reported no remaining NeoGenomics position as of Q1 2026 after selling out during the quarter.
Elequin Capital sold 6 NeoGenomics shares in Q1 2026, an estimated $71.
Elequin Capital first reported a position in NeoGenomics in Q1 2022 and held it in 9 quarters.
Elequin Capital's NeoGenomics position peaked at $2.51K in Q2 2023.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Elequin Capital's 13F filing for Q1 2026, filed 11 May 2026.